In reply: It is interesting that in the debate on prostate cancer screening, positions are not as far apart as a “debate” implies. I agree with Del Mar and colleagues that all the existing trials have “serious potential methodological flaws” and therefore cannot be taken as evidence that prostate-specific antigen (PSA) screening is effective — nor that it is ineffective. Both sides of the “debate” are consistent with the recent National Health and Medical Research Council conclusion that PSA testing may help some men and may not help others.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
No relevant disclosures.